N
PTGX icon

Natixis’s Protagonist Therapeutics PTGX Stock Holding History

Natixis’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$953K Buy
+7,776
New +$812K ﹤0.01% 755
2025
Q3 		– Sell
-42,040
Closed -$2.32M – 1199
2025
Q2 		$2.32M Buy
+42,040
New +$2.02M 0.01% 468

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Natixis's PTGX Position: Q2 2026 in Review

Natixis opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 7,776 shares worth $953K. The stake represents ﹤0.01% of the portfolio and ranks #755 among its holdings. This is a return to the name: Natixis previously reported a position in PTGX as recently as Q2 2025.

Natixis first reported a position in PTGX in Q2 2025 and has held it in 2 quarters since. The position peaked at $2.32M in Q2 2025. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Natixis held 7,776 shares of Protagonist Therapeutics worth $953K as of Q2 2026.
  • Protagonist Therapeutics was a new Natixis position in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Natixis's portfolio in Q2 2026, its #755 holding.
  • Natixis first reported a position in Protagonist Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • Natixis's Protagonist Therapeutics position peaked at $2.32M in Q2 2025.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.